Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04476017 · ClinicalTrials.gov registry record · Phase 2
A Study to Evaluate the Safety and Tolerability of SAGE-718 in Participants With Parkinson's Disease Mild Cognitive Impairment (PD-MCI)
A Phase 2 study, sponsored by Supernus Pharmaceuticals.
- Completed
- Registry status
- Phase 2
- Development phase
- 18
- Enrollment target
NCT04476017 is a Phase 2 study that has completed, run by Supernus Pharmaceuticals. The registered enrollment target is 18 participants.
The verdict
NCT04476017, a Phase 2 study, has completed, sponsored by Supernus Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 18 participants
- Enrollment target
Study Summary
The primary purpose of this two-part study was to evaluate the safety and tolerability of SAGE-718 and its effects on cognitive, neuropsychiatric, and motor symptoms in participants with Parkinson's disease mild cognitive impairment (PD-MCI).
Interventions
- DRUG SAGE-718
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 18 participants |
| Start Date | 2020-07-31 |
| Est. Completion | 2022-03-25 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04476017
The ClinicalTrials.gov registry entry for NCT04476017 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 18 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Supernus Pharmaceuticals, which has 57 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which SAGE-718 is the first listed.
NCT04476017 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04476017 about?
NCT04476017 is a clinical study titled "A Study to Evaluate the Safety and Tolerability of SAGE-718 in Participants With Parkinson's Disease Mild Cognitive Impairment (PD-MCI)". The primary purpose of this two-part study was to evaluate the safety and tolerability of SAGE-718 and its effects on cognitive, neuropsychiatric, and motor symptoms in participants with Parkinson's disease mild cognitive impairment (PD-MCI).
What is the current status of trial NCT04476017?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 18 participants. The study started on 2020-07-31. Estimated completion is 2022-03-25.
What interventions are being tested in trial NCT04476017?
The interventions under investigation include: SAGE-718 (DRUG).
Who is sponsoring clinical trial NCT04476017?
This trial is sponsored by Supernus Pharmaceuticals, which has 57 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.